Related Experiment Video

Updated: Aug 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Clopidogrel--statin interaction

James J Nawarskas1

  • 1University of New Mexico, College of Pharmacy, Albuquerque, NM., USA. nawarska@unm.edu

Cardiology in Review
|August 19, 2004
PubMed

Insights

Concerns exist about statins interfering with clopidogrel activation, potentially increasing thrombotic events. However, current evidence does not support changing prescribing patterns due to this potential drug interaction.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Interactions

Background:

  • Concerns exist regarding HMG CoA reductase inhibitors (statins) potentially inhibiting clopidogrel activation.
  • This interaction could increase the risk of thrombotic events in patients.

Observation:

  • Ex vivo studies have yielded conflicting results on the statin-clopidogrel interaction.
  • More recent retrospective studies suggest no increased thrombotic event rates when statins and clopidogrel are co-administered.
  • These observational studies compared patients on clopidogrel with a statin versus clopidogrel alone.

Findings:

  • The evidence from retrospective studies does not demonstrate a significant increase in myocardial infarction or stroke rates.
  • In vitro and retrospective data present a complex picture of the interaction's clinical significance.
  • A definitive conclusion awaits prospective studies evaluating combined versus monotherapy administration.

Implications:

  • The current body of evidence does not warrant altering prescribing habits solely to avoid a potential statin-clopidogrel interaction.
  • Further prospective research is needed to definitively resolve the debate on the clinical relevance of this drug interaction.
  • Clinicians should weigh the established benefits of statins and clopidogrel against the currently unproven risks of their co-administration.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...